{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,13]],"date-time":"2026-03-13T13:32:58Z","timestamp":1773408778354,"version":"3.50.1"},"reference-count":123,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Reproductive Toxicology"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1016\/j.reprotox.2010.04.015","type":"journal-article","created":{"date-parts":[[2010,5,5]],"date-time":"2010-05-05T08:58:47Z","timestamp":1273049927000},"page":"249-260","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":58,"title":["Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs)"],"prefix":"10.1016","volume":"30","author":[{"given":"Maria","family":"Ellfolk","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heli","family":"Malm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.reprotox.2010.04.015_bib1","first-page":"9","article-title":"Epidemiology of depression throughout the female life cycle","volume":"63","author":"Burt","year":"2002","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib2","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.ajog.2007.07.036","article-title":"Use of antidepressant medications during pregnancy: a multisite study","volume":"198","author":"Andrade","year":"2008","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib3","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1093\/humupd\/dmm019","article-title":"Mood disorders and fertility in women: a critical review of the literature and implications for future research","volume":"13","author":"Williams","year":"2007","journal-title":"Hum Reprod Update"},{"key":"10.1016\/j.reprotox.2010.04.015_bib4","unstructured":"NTP-CERHR Expert Panel Report on the reproductive and developmental toxicity of fluoxetine. Available at: (http:\/\/cerhr.niehs.nih.gov\/chemicals\/fluoxetine\/fluoxetine_final.pdf). Accessed 2010 February 10."},{"key":"10.1016\/j.reprotox.2010.04.015_bib5","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.fertnstert.2004.02.139","article-title":"A pilot study of the relationship between selective serotonin reuptake inhibitors and in vitro fertilization outcome","volume":"82","author":"Klock","year":"2004","journal-title":"Fertil Steril"},{"key":"10.1016\/j.reprotox.2010.04.015_bib6","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1016\/j.fertnstert.2009.03.060","article-title":"Effect of selective serotonin reuptake inhibitors on in vitro fertilization outcome","volume":"92","author":"Friedman","year":"2009","journal-title":"Fertil Steril"},{"key":"10.1016\/j.reprotox.2010.04.015_bib7","doi-asserted-by":"crossref","unstructured":"Tanrikut C, Feldman AS, Altemus M, Paduch DA, Schlegel PN. Adverse effect of paroxetine on sperm. Fertil Steril 2009 June 10. doi:10.1016\/j.fertnstert.2009.04.039.","DOI":"10.1016\/j.fertnstert.2009.04.039"},{"key":"10.1016\/j.reprotox.2010.04.015_bib8","doi-asserted-by":"crossref","first-page":"2124","DOI":"10.1016\/j.juro.2008.07.034","article-title":"Sperm DNA damage and semen quality impairment after treatment with selective serotonin reuptake inhibitors detected using semen analysis and sperm chromatin structure assay","volume":"180","author":"Safarinejad","year":"2008","journal-title":"J Urol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib9","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1097\/JCP.0b013e31817e6f80","article-title":"Evaluation of endocrine profile and hypothalamic-pituitary-testis axis in selective serotonin reuptake inhibitor-induced male sexual dysfunction","volume":"28","author":"Safarinejad","year":"2008","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib10","doi-asserted-by":"crossref","first-page":"2246","DOI":"10.1001\/jama.1993.03500170076037","article-title":"Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac)","volume":"269","author":"Pastuszak","year":"1993","journal-title":"JAMA"},{"key":"10.1016\/j.reprotox.2010.04.015_bib11","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1056\/NEJM199610033351402","article-title":"Birth outcomes in pregnant women taking fluoxetine","volume":"335","author":"Chambers","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib12","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1016\/S0029-7844(97)00070-7","article-title":"Effects of first-trimester fluoxetine exposure on the newborn","volume":"89","author":"Goldstein","year":"1997","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib13","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1001\/jama.279.8.609","article-title":"Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study","volume":"279","author":"Kulin","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.reprotox.2010.04.015_bib14","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1016\/j.ajog.2005.05.012","article-title":"Citalopram use in pregnancy: prospective comparative evaluation of pregnancy and fetal outcome","volume":"193","author":"Sivojelezova","year":"2005","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.reprotox.2008.06.006","article-title":"Statistical methods for estimating the probability of spontaneous abortion in observational studies\u2014analyzing pregnancies exposed to coumarin derivatives","volume":"26","author":"Meister","year":"2008","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib16","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/j.1600-0447.1989.tb07167.x","article-title":"The reproductive toxicology of paroxetine","volume":"350","author":"Baldwin","year":"1989","journal-title":"Acta Psychiatr Scand Suppl"},{"key":"10.1016\/j.reprotox.2010.04.015_bib17","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1006\/faat.1994.1058","article-title":"Developmental toxicology studies of fluoxetine hydrochloride administered orally to rats and rabbits","volume":"22","author":"Byrd","year":"1994","journal-title":"Fundam Appl Toxicol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib18","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1016\/j.reprotox.2009.04.005","article-title":"In vitro and in vivo reproduction toxicology of 12 monoaminergic reuptake inhibitors: possible mechanisms of infrequent cardiovascular anomalies","volume":"28","author":"Sloot","year":"2009","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib19","first-page":"75","article-title":"Serotonin and morphogenesis. Transient expression of serotonin uptake and binding protein during craniofacial morphogenesis in the mouse","volume":"187","author":"Shuey","year":"1993","journal-title":"Anat Embryol (Berl)"},{"key":"10.1016\/j.reprotox.2010.04.015_bib20","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijdevneu.2003.10.002","article-title":"Serotonin and its transporter on proliferation of fetal heart cells","volume":"21","author":"Sari","year":"2003","journal-title":"Int J Dev Neurosci"},{"key":"10.1016\/j.reprotox.2010.04.015_bib21","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.lfs.2008.10.008","article-title":"Estimation of embryotoxic effect of fluoxetine using embryonic stem cell differentiation system","volume":"83","author":"Kusakawa","year":"2008","journal-title":"Life Sci"},{"key":"10.1016\/j.reprotox.2010.04.015_bib22","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1176\/appi.ajp.160.5.993","article-title":"Placental passage of antidepressant medications","volume":"160","author":"Hendrick","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib23","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1055\/s-0028-1103296","article-title":"Placental transfer of SSRI and SNRI antidepressants and effects on the neonate","volume":"42","author":"Rampono","year":"2009","journal-title":"Pharmacopsychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib24","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1007\/s002280050664","article-title":"Delivery outcome after the use of antidepressants in early pregnancy","volume":"55","author":"Ericson","year":"1999","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib25","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1097\/01.AOG.0000187302.61812.53","article-title":"Risks associated with selective serotonin reuptake inhibitors in pregnancy","volume":"106","author":"Malm","year":"2005","journal-title":"Obstet Gynecol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib26","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1002\/pds.1462","article-title":"Risks of congenital malformations and perinatal events among infants exposed to antidepressant medication during pregnancy","volume":"16","author":"Davis","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.reprotox.2010.04.015_bib27","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1002\/bdra.20327","article-title":"Maternal use of selective serotonin re-uptake inhibitors in early pregnancy and infant congenital malformations","volume":"79","author":"K\u00e4ll\u00e9n","year":"2007","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib28","doi-asserted-by":"crossref","first-page":"2675","DOI":"10.1056\/NEJMoa067407","article-title":"First trimester use of selective serotonin-reuptake inhibitors and the risk of birth defects","volume":"356","author":"Louik","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib29","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1177\/070674370905400405","article-title":"Incidence of major malformations in infants following antidepressant exposure in pregnancy: results of a large prospective cohort study","volume":"54","author":"Einarson","year":"2009","journal-title":"Can J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib30","doi-asserted-by":"crossref","unstructured":"Reis M, K\u00e4ll\u00e9n B. Delivery outcome after maternal use of antidepressant drugs in pregnancy: an update using Swedish data. Psychol Med 2010:1\u201311. doi:10.1017\/S0033291709992194.","DOI":"10.1017\/S0033291709992194"},{"key":"10.1016\/j.reprotox.2010.04.015_bib31","doi-asserted-by":"crossref","first-page":"23","DOI":"10.4065\/84.1.23","article-title":"Congenital heart disease associated with selective serotonin reuptake inhibitor use during pregnancy","volume":"84","author":"Wichman","year":"2009","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.reprotox.2010.04.015_bib32","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1002\/bdrb.20144","article-title":"Major congenital malformations following prenatal exposure to serotonin reuptake inhibitors and benzodiazepines using population-based health data","volume":"83","author":"Oberlander","year":"2008","journal-title":"Birth Defects Res B Dev Reprod Toxicol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1002\/bdra.20615","article-title":"Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur","volume":"85","author":"Merlob","year":"2009","journal-title":"Birth Defects Res A Clin Mol Teratol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib34","doi-asserted-by":"crossref","unstructured":"Pedersen LH, Henriksen TB, Vestergaard M, Olsen J, Bech BH. Selective serotonin reuptake inhibitors in pregnancy and congenital malformations: population based cohort study. BMJ 2009;339 (September):b3569 doi:10.1136\/bmj.b4569.","DOI":"10.1136\/bmj.b3569"},{"key":"10.1016\/j.reprotox.2010.04.015_bib35","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1056\/NEJMoa066584","article-title":"(National Birth defects Prevention study). Use of selective serotonin-reuptake inhibitors in pregnancy and the risk of birth defects","volume":"356","author":"Alwan","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib36","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/j.1365-2125.2008.03261.x","article-title":"Paroxetine and fluoxetine in pregnancy: a prospective, multicentre, controlled, observational study","volume":"66","author":"Diav-Citrin","year":"2008","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib37","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1002\/pds.1463","article-title":"Paroxetine in the first trimester and the prevalence of congenital malformations","volume":"16","author":"Cole","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.reprotox.2010.04.015_bib38","first-page":"459","article-title":"Paroxetine and fluoxetine in pregnancy: a multi-center, prospective, controlled study (abstract)","volume":"20","author":"Diav-Citrin","year":"2005","journal-title":"Reprod Toxicol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib39","doi-asserted-by":"crossref","unstructured":"Bakker MK, Kerstjens-Frederikse WS, Buys CHCM, de Walle HEK, de Jong-van den Berg LTW. First trimester use of paroxetine and congenital heart defects: A population based case\u2013control study. Birth Defects Res A Clin Mol Teratol 2010;88:94\u2013100. Epub 2009 November 20.","DOI":"10.1002\/bdra.20641"},{"key":"10.1016\/j.reprotox.2010.04.015_bib40","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.clinthera.2007.05.003","article-title":"Paroxetine and congenital malformations: meta-analysis and consideration of potential confounding factors","volume":"29","author":"Bar-Oz","year":"2007","journal-title":"Clin Ther"},{"key":"10.1016\/j.reprotox.2010.04.015_bib41","doi-asserted-by":"crossref","unstructured":"Wurst KE, Poole C, Ephross SA, Olshan AF. First trimester paroxetine use and the prevalence of congenital, specifically cardiac, defects: A meta-analysis of epidemiological studies. Birth Defects Res A Clin Mol Teratol 2009 September 8. doi:10.1002\/bdra.20627.","DOI":"10.1002\/bdra.20627"},{"key":"10.1016\/j.reprotox.2010.04.015_bib42","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1176\/appi.ajp.2007.07060879","article-title":"Evaluation of the risk of congenital cardiovascular defects associated with use of paroxetine during pregnancy","volume":"165","author":"Einarson","year":"2008","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib43","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1001\/archpedi.156.11.1129","article-title":"Perinatal outcome following third trimester exposure to paroxetine","volume":"156","author":"Costei","year":"2002","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib44","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1001\/archpedi.158.4.312","article-title":"Neonate characteristics after maternal use of antidepressants in late pregnancy","volume":"158","author":"Kallen","year":"2004","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib45","doi-asserted-by":"crossref","first-page":"2055","DOI":"10.1176\/appi.ajp.159.12.2055","article-title":"Outcomes of prenatal antidepressant exposure","volume":"159","author":"Simon","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib46","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.ajog.2006.02.019","article-title":"Selective serotonin reuptake inhibitors and adverse pregnancy outcomes","volume":"194","author":"Wen","year":"2006","journal-title":"Am J Obstet Gynecol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib47","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1001\/archpediatrics.2009.164","article-title":"Selective serotonin reuptake inhibitor exposure in utero and pregnancy outcomes","volume":"163","author":"Lund","year":"2009","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib48","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1176\/appi.ajp.2008.08081170","article-title":"Major depression and antidepressant treatment: impact on pregnancy and neonatal outcomes","volume":"166","author":"Wisner","year":"2009","journal-title":"Am Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib49","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1007\/s00737-004-0057-5","article-title":"The impact of depression and fluoxetine treatment on obstetrical outcome","volume":"7","author":"Suri","year":"2004","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.reprotox.2010.04.015_bib50","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1001\/archpsyc.63.8.898","article-title":"Neonatal outcomes after prenatal exposure to selective serotonin reuptake inhibitor antidepressants and maternal depression using population-based linked health data","volume":"63","author":"Oberlander","year":"2006","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib51","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1097\/JCP.0b013e3181bf344c","article-title":"Antidepressant use during pregnancy and the risk of preterm delivery and fetal growth restriction","volume":"29","author":"Toh","year":"2009","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib52","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1192\/bjp.bp.107.037101","article-title":"Effects of timing and duration of gestational exposure to serotonin reuptake inhibitor antidepressants: population-based study","volume":"192","author":"Oberlander","year":"2008","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib53","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1093\/humrep\/den342","article-title":"Presence of depressive symptoms during early pregnancy and the risk of preterm delivery: a prospective cohort study","volume":"24","author":"Li","year":"2009","journal-title":"Hum Reprod"},{"key":"10.1016\/j.reprotox.2010.04.015_bib54","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1089\/jwh.2009.1387","article-title":"Maternal and fetal outcomes among women with depression","volume":"19","author":"Bansil","year":"2010","journal-title":"J Womens Health (Larchmt)"},{"key":"10.1016\/j.reprotox.2010.04.015_bib55","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1016\/S0140-6736(05)17865-9","article-title":"Selective serotonin reuptake inhibitors in pregnant women and neonatal withdrawal syndrome: a database analysis","volume":"365","author":"Sanz","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.reprotox.2010.04.015_bib56","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/archpedi.160.2.173","article-title":"Neonatal abstinence syndrome after in utero exposure to selective serotonin reuptake inhibitors in term infants","volume":"160","author":"Levinson-Castiel","year":"2006","journal-title":"Arch Pediatr Adolesc Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib57","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/sj.jp.7211352","article-title":"Selective serotonin reuptake inhibitor (SSRI) use during pregnancy and effects on the fetus and newborn: a meta-analysis","volume":"25","author":"Lattimore","year":"2005","journal-title":"J Perinatol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib58","doi-asserted-by":"crossref","unstructured":"Warburton W, Hertzman C, Oberlander TF. A register study of the impact of stopping third trimester selective serotonin reuptake inhibitor exposure on neonatal health. Acta Psychiatr Scand 2009:1\u20139. doi:10.1111\/j.1600-0447.2009.01490.","DOI":"10.1111\/j.1600-0447.2009.01490.x"},{"key":"10.1016\/j.reprotox.2010.04.015_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1097\/01.ftd.0000187971.95000.25","article-title":"Paroxetine toxicity in a newborn after in utero exposure: clinical symptoms correlate with serum levels","volume":"28","author":"Knoppert","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.reprotox.2010.04.015_bib60","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1001\/archpsyc.60.7.720","article-title":"Effects of exposure to selective serotonin reuptake inhibitors during pregnancy on serotonergic symptoms in newborns and cord blood monoamine and prolactinconcentrations","volume":"60","author":"Laine","year":"2003","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib61","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1097\/00007691-200412000-00016","article-title":"Severe adverse effects in a newborn with two defective CYP2D6 alleles after exposure to paroxetine during late pregnancy","volume":"26","author":"Laine","year":"2004","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.reprotox.2010.04.015_bib62","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1038\/sj.mp.4002007","article-title":"Infant serotonin transporter (SLC6A4) promoter genotype is associated with adverse neonatal outcomes after prenatal exposure to serotonin reuptake inhibitor medications","volume":"13","author":"Oberlander","year":"2008","journal-title":"Mol Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib63","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.euroneuro.2009.01.006","article-title":"MAO-A and COMT genotypes as possible regulators of perinatal serotonergic symptoms after in utero exposure to SSRIs","volume":"19","author":"Hilli","year":"2009","journal-title":"Eur Neuropsychopharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib64","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1053\/j.semperi.2005.02.003","article-title":"The diseases treated with ECMO: focus on PPHN","volume":"29","author":"Farrow","year":"2005","journal-title":"Semin Perinatol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib65","doi-asserted-by":"crossref","first-page":"e272","DOI":"10.1542\/peds.2006-3037","article-title":"Risk factors for persistent pulmonary hypertension of the newborn","volume":"120","author":"Hernandez-Diaz","year":"2007","journal-title":"Pediatrics"},{"key":"10.1016\/j.reprotox.2010.04.015_bib66","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1056\/NEJMoa052744","article-title":"Selective serotonin-reuptake inhibitors and risk of persistent pulmonary hypertension of the newborn","volume":"354","author":"Chambers","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib67","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1002\/pds.1570","article-title":"Maternal use of selective serotonin re-uptake inhibitors and persistent pulmonary hypertension of the newborn","volume":"17","author":"K\u00e4ll\u00e9n","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.reprotox.2010.04.015_bib68","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/pds.1710","article-title":"Antidepressant medication use and risk of persistent pulmonary hypertension of the newborn","volume":"18","author":"Andrade","year":"2009","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.reprotox.2010.04.015_bib69","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1056\/NEJM199701233360404","article-title":"Neurodevelopment of children exposed in utero to antidepressant drugs","volume":"336","author":"Nulman","year":"1997","journal-title":"N Engl J Med"},{"key":"10.1016\/j.reprotox.2010.04.015_bib70","doi-asserted-by":"crossref","first-page":"1889","DOI":"10.1176\/appi.ajp.159.11.1889","article-title":"Child development following exposure to tricyclic antidepressants or fluoxetine throughout fetal life: a prospective, controlled study","volume":"159","author":"Nulman","year":"2002","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib71","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mcp.2002.126181","article-title":"Citalopram in pregnancy and lactation","volume":"72","author":"Heikkinen","year":"2002","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.reprotox.2010.04.015_bib72","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.earlhumdev.2008.06.008","article-title":"Hypothalamic-pituitary-adrenal (HPA) axis function in 3-month old infants with prenatal selective serotonin reuptake inhibitor (SSRI) antidepressant exposure","volume":"84","author":"Oberlander","year":"2008","journal-title":"Early Hum Dev"},{"key":"10.1016\/j.reprotox.2010.04.015_bib73","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1542\/peds.2004-0420","article-title":"Pain reactivity in 2-month-old infants after prenatal and postnatal serotonin reuptake inhibitor medication exposure","volume":"115","author":"Oberlander","year":"2005","journal-title":"Pediatrics"},{"key":"10.1016\/j.reprotox.2010.04.015_bib74","doi-asserted-by":"crossref","first-page":"1002","DOI":"10.1038\/nrn1256","article-title":"The developmental role of serotonin: news from mouse molecular genetics","volume":"4","author":"Gaspar","year":"2003","journal-title":"Nat Rev Neurosci"},{"key":"10.1016\/j.reprotox.2010.04.015_bib75","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.tips.2009.11.003","article-title":"New perspectives on the neurodevelopmental effects of SSRIs","volume":"31","author":"Homberg","year":"2010","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.reprotox.2010.04.015_bib76","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1523\/JNEUROSCI.3973-07.2008","article-title":"Inhibition of serotonin but not norepinephrine transport during development produces delayed, persistent perturbations of emotional behaviors in mice","volume":"28","author":"Ansorge","year":"2008","journal-title":"J Neurosci"},{"key":"10.1016\/j.reprotox.2010.04.015_bib77","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.biopsych.2003.09.003","article-title":"Abnormal behavioral phenotypes of serotonin transporter knockout mice: parallels with human anxiety and depression","volume":"54","author":"Holmes","year":"2003","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib78","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1038\/clpt.2009.201","article-title":"Ansorge MS. neurobehavioral effects of exposure to SSRI antidepressants during development: molecular to clinical evidence","volume":"86","author":"Oberlander","year":"2009","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.reprotox.2010.04.015_bib79","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clp.2009.06.002","article-title":"Fetal effects of psychoactive drugs","volume":"36","author":"Salisbury","year":"2009","journal-title":"Clin Perinatol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib80","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1210\/jc.2009-1575","article-title":"Horseman ND Serotonin transport and metabolism in the mammary gland modulates secretory activation and involution","volume":"95","author":"Marshall","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.reprotox.2010.04.015_bib81","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/j.1552-4604.1996.tb04150.x","article-title":"Excretion of fluoxetine and its metabolite, norfluoxetine, in human breast milk","volume":"36","author":"Taddio","year":"1996","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib82","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1192\/bjp.172.2.175","article-title":"Fluoxetine in breast-milk and developmental outcome of breast-fed infants","volume":"172","author":"Yoshida","year":"1998","journal-title":"Br J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib83","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1046\/j.1365-2125.1999.00040.x","article-title":"Distribution and excretion of fluoxetine and norfluoxetine in human milk","volume":"48","author":"Kristensen","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib84","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.4088\/JCP.v65n0911","article-title":"Breastfeeding during maternal antidepressant treatment with serotonin reuptake inhibitors: infant exposure, clinical symptoms, and cytochrome p450 genotypes","volume":"65","author":"Berle","year":"2004","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib85","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1111\/j.1365-2125.2005.02538.x","article-title":"Stereoselective disposition of fluoxetine and norfluoxetine during pregnancy and breast-feeding","volume":"61","author":"Kim","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib86","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0006-3223(01)01197-0","article-title":"Fluoxetine and norfluoxetine concentrations in nursing infants and breast milk","volume":"50","author":"Hendrick","year":"2001","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib87","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/S0006-3223(02)01368-9","article-title":"Estimates of nursing infant daily dose of fluoxetine through breast milk","volume":"52","author":"Suri","year":"2002","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib88","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/S0009-9236(02)17634-X","article-title":"Pharmacokinetics of fluoxetine and norfluoxetine in pregnancy and lactation","volume":"73","author":"Heikkinen","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.reprotox.2010.04.015_bib89","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1097\/00004583-199311000-00020","article-title":"Possible association between fluoxetine hydrochloride and colic in an infant","volume":"32","author":"Lester","year":"1993","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib90","first-page":"169","article-title":"Excretion of fluoxetine in human breast milk","volume":"51","author":"Isenberg","year":"1990","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib91","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1176\/appi.ajp.161.6.1066","article-title":"Pooled analysis of antidepressant levels in lactating mothers, breast milk, and nursing infants","volume":"161","author":"Weissman","year":"2004","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib92","doi-asserted-by":"crossref","first-page":"e425","DOI":"10.1542\/peds.112.5.e425","article-title":"Maternal fluoxetine treatment in the postpartum period: effects on platelet serotonin and plasma drug levels in breastfeeding mother-infant pairs","volume":"112","author":"Epperson","year":"2003","journal-title":"Pediatrics"},{"key":"10.1016\/j.reprotox.2010.04.015_bib93","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s00737-007-0173-0","article-title":"SSRIs during breastfeeding: spotlight on milk-to-plasma ratio","volume":"10","author":"Gentile","year":"2007","journal-title":"Arch Womens Ment Health"},{"key":"10.1016\/j.reprotox.2010.04.015_bib94","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1097\/00007691-199704000-00021","article-title":"Citalopram and desmethylcitalopram concentrations in breast milk and in serum of mother and infant","volume":"19","author":"Jensen","year":"1997","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.reprotox.2010.04.015_bib95","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1365-2125.1997.t01-1-00576.x","article-title":"Excretion of citalopram in breast milk","volume":"44","author":"Spigset","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib96","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1046\/j.1365-2125.2000.00253.x","article-title":"Citalopram and demethylcitalopram in human milk; distribution, excretion and effects in breast fed infants","volume":"50","author":"Rampono","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib97","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0006-3223(99)00155-9","article-title":"Citalopram and breast-feeding: serum concentration and side effects in the infant","volume":"47","author":"Schmidt","year":"2000","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib98","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1097\/01.ftd.0000187972.02624.2e","article-title":"Citalopram serum and milk levels in mother and infant during lactation","volume":"28","author":"Franssen","year":"2006","journal-title":"Ther Drug Monit"},{"key":"10.1016\/j.reprotox.2010.04.015_bib99","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1097\/01.jcp.0000231607.45402.b4","article-title":"Excretion of escitalopram in breast milk","volume":"26","author":"Castberg","year":"2006","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib100","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1111\/j.1365-2125.2006.02659.x","article-title":"Transfer of escitalopram and its metabolite demethylescitalopram into breastmilk","volume":"62","author":"Rampono","year":"2006","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib101","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/S0002-9378(03)00868-8","article-title":"Frequency of infant adverse events that are associated with citalopram use during breast-feeding","volume":"190","author":"Lee","year":"2004","journal-title":"Am J Obstet Gynecol."},{"key":"10.1016\/j.reprotox.2010.04.015_bib102","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1038\/sj.jp.7211640","article-title":"Necrotizing enterocolitis associated with in utero and breast milk exposure to the selective serotonin reuptake inhibitor, escitalopram","volume":"27","author":"Potts","year":"2007","journal-title":"J Perinatol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib103","first-page":"39","article-title":"Paroxetine level in breast milk","volume":"57","author":"Spigset","year":"1996","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib104","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1046\/j.1365-2125.1999.00992.x","article-title":"Paroxetine in human milk","volume":"48","author":"Begg","year":"1999","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib105","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1176\/appi.ajp.157.2.185","article-title":"Paroxetine in human breast milk and nursing infants","volume":"157","author":"Stowe","year":"2000","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib106","doi-asserted-by":"crossref","first-page":"519","DOI":"10.4088\/JCP.v60n0803","article-title":"Excretion of paroxetine into breast milk","volume":"60","author":"Ohman","year":"1999","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib107","doi-asserted-by":"crossref","first-page":"828","DOI":"10.4088\/JCP.v61n1104","article-title":"Paroxetine levels in postpartum depressed women, breast milk, and infant serum","volume":"61","author":"Misri","year":"2000","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib108","first-page":"243","article-title":"Breastfeeding and sertraline: a 24-hour analysis","volume":"56","author":"Altshuler","year":"1995","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib109","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1046\/j.1365-2125.1998.00705.x","article-title":"Distribution and excretion of sertraline and N-desmethylsertraline in human milk","volume":"45","author":"Kristensen","year":"1998","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib110","doi-asserted-by":"crossref","first-page":"100","DOI":"10.4088\/JCP.v58n0302","article-title":"Sertraline and norsertraline levels in three breastfed infants","volume":"58","author":"Mammen","year":"1997","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib111","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1176\/ajp.154.9.1255","article-title":"Sertraline and desmethylsertraline in human breast milk and nursing infants","volume":"154","author":"Stowe","year":"1997","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib112","doi-asserted-by":"crossref","first-page":"1631","DOI":"10.1176\/appi.ajp.158.10.1631","article-title":"Maternal sertraline treatment and serotonin transport in breast-feeding mother-infant pairs","volume":"158","author":"Epperson","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib113","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1046\/j.1365-2125.2000.00142-3.x","article-title":"Excretion of fluvoxamine into breast milk","volume":"49","author":"H\u00e4gg","year":"2000","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib114","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1111\/bcp.1997.44.2.210","article-title":"Fluvoxamine in breast-milk and infant development","volume":"44","author":"Yoshida","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib115","doi-asserted-by":"crossref","first-page":"111","DOI":"10.4088\/JCP.v62n0207","article-title":"Serum fluvoxamine levels in breastfed infants","volume":"62","author":"Piontek","year":"2001","journal-title":"J Clin Psychiatry"},{"key":"10.1016\/j.reprotox.2010.04.015_bib116","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1177\/089033440201800205","article-title":"The amount of fluvoxamine in milk is unlikely to be a cause of adverse effects in breastfed infants","volume":"18","author":"Kristensen","year":"2002","journal-title":"J Hum Lact"},{"key":"10.1016\/j.reprotox.2010.04.015_bib117","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1097\/00004714-200008000-00018","article-title":"Fluvoxamine concentrations in breast milk and in maternal and infant sera","volume":"20","author":"Arnold","year":"2000","journal-title":"J Clin Psychopharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib118","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/(SICI)1096-9926(199907)60:1<33::AID-TERA9>3.0.CO;2-X","article-title":"Improvement of drug exposure data in a registration of congenital anomalies. Pilot-study: pharmacist and mother as sources for drug exposure data during pregnancy. EuroMAP Group. European Medicine and Pregnancy Group","volume":"60","author":"de Jong van den Berg","year":"1999","journal-title":"Teratology"},{"key":"10.1016\/j.reprotox.2010.04.015_bib119","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1007\/s00228-003-0584-4","article-title":"Prescription drugs during pregnancy and lactation\u2014a Finnish register-based study","volume":"59","author":"Malm","year":"2003","journal-title":"Eur J Clin Pharmacol"},{"key":"10.1016\/j.reprotox.2010.04.015_bib120","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1002\/pds.766","article-title":"Validation studies of drug exposures in pregnant women","volume":"12","author":"Czeizel","year":"2003","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.reprotox.2010.04.015_bib121","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1067\/mpd.2003.243","article-title":"Temporal variability in birth prevalence of congenital heart defects as recorded by a general birth defects registry","volume":"142","author":"Bosi","year":"2003","journal-title":"J Pediatr"},{"key":"10.1016\/j.reprotox.2010.04.015_bib122","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1097\/01.ede.0000239581.76793.ae","article-title":"Maternal use of selective serotonin reuptake inhibitors and risk of congenital malformations","volume":"17","author":"Wogelius","year":"2006","journal-title":"Epidemiology"},{"key":"10.1016\/j.reprotox.2010.04.015_bib123","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1002\/bdrb.20099","article-title":"First trimester exposure to paroxetine and risk of cardiac malformations in infants: the importance of dosage","volume":"80","author":"B\u00e9rard","year":"2007","journal-title":"Birth Defects Res B Dev Reprod Toxicol"}],"container-title":["Reproductive Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623810000936?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890623810000936?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:30:02Z","timestamp":1760189402000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890623810000936"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":123,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0890623810000936"],"URL":"https:\/\/doi.org\/10.1016\/j.reprotox.2010.04.015","relation":{},"ISSN":["0890-6238"],"issn-type":[{"value":"0890-6238","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Risks associated with in utero and lactation exposure to selective serotonin reuptake inhibitors (SSRIs)","name":"articletitle","label":"Article Title"},{"value":"Reproductive Toxicology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.reprotox.2010.04.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}